These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23364325)

  • 1. Intravitreal bevacizumab for type 2 idiopathic macular telangiectasia.
    Veloso CE; Vianna RN; Pelayes DE; Nehemy MB
    Ophthalmic Res; 2013; 49(4):205-8. PubMed ID: 23364325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia.
    Roller AB; Folk JC; Patel NM; Boldt HC; Russell SR; Abramoff MD; Mahajan VB
    Retina; 2011 Oct; 31(9):1848-55. PubMed ID: 21610563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia.
    Charbel Issa P; Holz FG; Scholl HP
    Ophthalmology; 2007 Sep; 114(9):1736-42. PubMed ID: 17822979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II.
    Kovach JL; Rosenfeld PJ
    Retina; 2009 Jan; 29(1):27-32. PubMed ID: 18936721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal bevacizumab for perifoveal telangiectasia.
    Jonas JB; Libondi T; von Baltz S; Beutelspacher S
    Acta Ophthalmol; 2011 Nov; 89(7):e607-8. PubMed ID: 20946328
    [No Abstract]   [Full Text] [Related]  

  • 7. Intravitreal bevacizumab for type 1 idiopathic macular telangiectasia.
    Takayama K; Ooto S; Tamura H; Yamashiro K; Otani A; Tsujikawa A; Yoshimura N
    Eye (Lond); 2010 Sep; 24(9):1492-7. PubMed ID: 20431610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of anti-vascular endothelial growth factor therapy in subretinal neovascularization secondary to macular telangiectasia type 2.
    Narayanan R; Chhablani J; Sinha M; Dave V; Tyagi M; Pappuru RR; Kuppermann BD
    Retina; 2012; 32(10):2001-5. PubMed ID: 22990322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study.
    Charbel Issa P; Finger RP; Kruse K; Baumüller S; Scholl HP; Holz FG
    Am J Ophthalmol; 2011 May; 151(5):876-886.e1. PubMed ID: 21334595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections.
    Mekjavic PJ; Kraut A; Urbancic M; Lenassi E; Hawlina M
    Acta Ophthalmol; 2011 Nov; 89(7):647-53. PubMed ID: 19860774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema.
    Soheilian M; Ramezani A; Obudi A; Bijanzadeh B; Salehipour M; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Peyman GA
    Ophthalmology; 2009 Jun; 116(6):1142-50. PubMed ID: 19376585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial.
    Ahmadieh H; Taei R; Riazi-Esfahani M; Piri N; Homayouni M; Daftarian N; Yaseri M
    Retina; 2011 Oct; 31(9):1819-26. PubMed ID: 21555967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion.
    Singer MA; Bell DJ; Woods P; Pollard J; Boord T; Herro A; Porbandarwalla S
    Retina; 2012 Jul; 32(7):1289-94. PubMed ID: 22466480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
    Solaiman KA; Diab MM; Abo-Elenin M
    Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long term result of intravitreal bevacizumab in a patient newly transformed to proliferative macular telangiectasia type 2.
    Ozkaya A; Alkin Z; Karakucuk Y; Yazici AT; Demirok A
    Middle East Afr J Ophthalmol; 2013; 20(4):360-2. PubMed ID: 24339691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of fundus autofluorescence with spectral-domain optical coherence tomography and vision in diabetic macular edema.
    Chung H; Park B; Shin HJ; Kim HC
    Ophthalmology; 2012 May; 119(5):1056-65. PubMed ID: 22342014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thirty-month follow-up after intravitreal bevacizumab in progressive idiopathic macular telangiectasia type 2.
    Matt G; Sacu S; Ahlers C; Schütze C; Dunavoelgyi R; Prager F; Pruente C; Schmidt-Erfurth U
    Eye (Lond); 2010 Oct; 24(10):1535-41; quiz 1542. PubMed ID: 20865030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
    Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Vascular Endothelial Growth Factor Treatment for Proliferative Macular Telangiectasia Type 2.
    Alkin Z; Yilmaz I; Ozkaya A; Yazici AT
    Middle East Afr J Ophthalmol; 2016; 23(2):222-4. PubMed ID: 27162458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.